CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs.…
A BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
mantle cell lymphoma
Dr Reddy’s announce launch of Bortezomib for injection, 3.5 mg single-dose vial in US
Bortezomib for injection is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma and mantle…
AztraZeneca to launch oncology drug Calquence in India
It is used to treat mantle cell lymphoma and chronic lymphocytic leukaemia
FDA approves Tecartus, cell-based gene therapy to treat relapsed or refractory MCL in adults
It also received ‘Orphan Drug’ designation, which provides incentives to assist and encourage the development of drugs for rare…
FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma
Mantle cell lymphoma is a type of non-Hodgkin’s lymphoma representing three to ten per cent of all non-Hodgkin’s lymphomas in the…